Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Publication

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Caroline Tosch, et al. Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article Publication

Published 12 October 2017
Categorized as -others, 2017, Publication, TG4010

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

Christelle Remy-Ziller, et al. Human Vaccines & Immunotherapeutics, 2017, 19:0 – Download the article Publication

Published 12 October 2017
Categorized as -others, 2017, Publication, TG4010

A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8 Download the poster here Poster Presentation

Published 7 September 2017
Categorized as -others, 2017, Pexa-Vec, Publication Tagged Oncolytic virus, Poster presentation

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer

K. Bendjama, E. Quéméneur Human Vaccines and Immunotherapeutics, August 2017 – Read the article Publication

Published 26 August 2017
Categorized as 2017, Myvac, Publication, publication key en, TG4050

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 – Download the article Publication

Published 24 July 2017
Categorized as -others, 2017, Publication, TG6002

TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma

Ahmed Idbaih, et al. ASCO 2017, June 2017 – Download the abstract Abstract

Published 5 June 2017
Categorized as -others, 2017, Publication, TG6002

Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade

Laetitia Fend, et al.AACR, American Association for cancer Research, April 2017Download the poster herePoster Presentation

Published 5 April 2017
Categorized as -others, 2017, Publication, TG1050

In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC

Sandrine Cochin, et al. CLARA, Forum de la recherche en cancérologie, April 2017 Download the poster here Poster Presentation

Published 2 April 2017
Categorized as -others, 2017, Publication Tagged Oncolytic virus, Poster presentation

Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine

Faleh Husseini, et al.Annals of Oncology, February 2017, DOI: https://doi.org/10.1093/annonc/mdw440 – Download the articlePublication TG4023 is a non-replicative MVA integrating the FCU1 gene that has been inserted in the oncolytic virus TG6002.

Published 22 February 2017
Categorized as 2017, Publication

Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen

Gilda G. Hillman, et al. Journal for ImmunoTherapy of Cancer, January 2017 – Download the article Publication

Published 20 January 2017
Categorized as -others, 2017, Publication Tagged Poster presentation, Therapeutic Vaccine

Posts pagination

Newer posts Page 1 … Page 9 … Page 13 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu